1/21/2013

Greater buildup of beta amyloid in the brain as measured through 18F-florbetaben PET imaging correlated with declining cognitive capability in older patients with mild impairment, according to a study in Alzheimer's Research and Therapy. Based on previous PiB-based studies, researchers said the current findings indicate beta amyloid accumulation in patients with higher florbetaben (FBB) absorption could lead to symptoms of Alzheimer's disease in five to seven years. "Moreover, the use of FBB may prove useful in the early differential diagnosis of mild cognitive impairment ... potentially aiding early therapeutic interventions as well as helping to predict prognosis," according to researchers.

Related Summaries